

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



四环医药  
*SihuanPharm*

**Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0460)**

**VOLUNTARY ANNOUNCEMENT**  
**THE SUBMISSION OF PHASE II CLINICAL RESULTS OF**  
**XUANZHU BIOPHARMACEUTICAL'S CLASS 1**  
**INNOVATIVE DRUG BIROCICLIB WAS ACCEPTED BY**  
**2023 ASCO ANNUAL MEETING**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the abstract of phase II clinical results of class 1 innovative drug under development Birociclib (XZP-3287 CDK4/6 inhibitor), titled “A multicenter, single-arm, open-label trial of Birociclib, CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer”, was submitted by Xuanzhu Biopharmaceutical Co., Ltd. (“**Xuanzhu Biopharmaceutical**”), a non-wholly owned subsidiary of the Group, to the ASCO (American Society of Clinical Oncology) Annual Meeting on 10 February 2023 and was recently selected for presentation in a Poster Session on 4 June 2023.

The main content of this submission includes clinical study design, clinical results (drug exposure, efficacy, and safety results). The submission elaborated on the efficacy advantages of Birociclib’s monotherapy, reflecting the differentiated characteristics and clinical value of the product.

The ASCO Annual Meeting is the world's largest, most academically advanced and most authoritative clinical conference of oncology. Characterized by exhibiting fundamental research and the latest clinical research of oncology, it discusses advanced treatment methods currently in the world. The selection of Xuanzhu Biopharmaceutical's submission indicates that the results of the Phase II study of Birociclib's monotherapy attracted the attention of the reviewers of ASCO Scientific Program Committee who pursue innovation and advancement. This shows that the efficacy advantages of Birociclib's monotherapy have obvious differentiated characteristics, which are recognized by professionals.

## **About Birociclib**

The phase I clinical data demonstrated that Birociclib, a novel selective CDK4/6 inhibitor, has the potential to overcome endocrine therapy resistance in hormone receptor-positive (HR+) breast cancer patients. Birociclib monotherapy also exhibited efficacy in patients with advanced breast cancer who have failed in multiple lines of treatment. Pre-clinical data showed that Birociclib has a unique pharmacokinetic profile, which allows it to go through the blood-brain barrier effectively, and thus it is expected to have potential efficacy in breast cancer patients with brain metastases and brain tumor patients. Moreover, due to the novel targeting mechanism of CDK4/6, Birociclib is able to demonstrate significant clinical benefits and extensive market prospect through multiple novel Birociclib-based combination therapies.

## **About Xuanzhu Biopharmaceutical**

Xuanzhu Biopharmaceutical is the innovative drug subsidiary of Sihuan Pharmaceutical. It is an innovative pharmaceutical company with roots in China and a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the continuous research and development, production and commercialization of class 1 drugs with core proprietary intellectual property rights to address unmet clinical medical needs. The company has a team with extensive experience in the development and industrialisation of innovative drugs. Having been involved in the research of digestion, oncology and non-alcoholic steatohepatitis for many years, the company has a deep understanding and international vision of the development of new drugs in related fields and their future development direction. The company has two R&D platforms: small molecule chemistry and large molecule biologics. The dual engines drive the company's innovation and development, forming a product pipeline that covers small molecule, monoclonal antibodies, bispecific antibodies, antibody-drug conjugate (ADC) and other types of products. The company adheres to the strategic concept of "innovation driven, promoting the development of new drugs in China and serving human health", and the values of "open innovation, courageous commitment, overcoming difficulties and scientific rigor". With a focus on unmet clinical needs, the company continues to develop new class 1 drugs with international competitiveness, and is committed to developing into a first-class innovative pharmaceutical company with independent research and development, production, and sales capabilities.

## About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and biopharmaceutical company led and driven by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic objective of “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavours to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Group on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 14 April 2023

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.*